Table 4.
Effect of cardiac shock wave therapy in human controlled studies: clinical and quality of life parameters
| Period | CCS angina class | Nitroglycerine consumption | NYHA class | Seattle angina questionnaire | ||
|---|---|---|---|---|---|---|
| P. Yang 2013 [79] | Test group (N=14) | Baseline | 2.0 (1.0, 3.0) | 2.0 (0.0, 3.0) | 2.0 (1.0, 2.0) | 73.5 (60.5, 81.0) |
| Post treatment | 1.0 (1.0, 2.0)* | 1.0 (0.0, 2.0) | 1.0 (1.0, 1.0)* | 82.0 (74.5, 88.0)* | ||
| Placebo group (N=11) | Baseline | 2.0 (1.0, 3.0) | 2.0 (1.0, 3.0) | 1.0 (1.0, 2.0) | 73.0 (63.0, 80.0) | |
| Post treatment | 2.0 (1.0, 2.0) | 2.0 (0.0, 2.0) | 2.0 (1.0, 2.0) | 78.0 (69.0, 85.0) | ||
| Y. Wang 2012 [24] | I group (standard treatment) (N=20) | Baseline | 2 (1, 2) | 1 (0, 2) | 1.5 (1, 3) | 64.9±11.72 |
| Post treatment | 1 (1, 1)* | 0 (0, 1) | 1 (1, 1) | 75.0±10.45* | ||
| II group (modified treatment) (N=21) | Baseline | 3 (2, 3) | 2 (0, 3) | 2 (1, 2.5) | 67.9±13.0 | |
| Post treatment | 2 (1, 2) | 0 (0, 1) | 1 (1, 1) | 76.14±12.28 | ||
| Control group (N=14) | Baseline | 2 (2, 3) | 1 (0, 4) | 2 (1, 3) | 63.21±11.89 | |
| Post treatment | 2 (1, 2.3) | 0 (0, 2) | 1 (1, 2.3) | 60.14±12.82 | ||
| P. Yang 2012 [76] | Test group (N=25) | Baseline | 2.72±0.46 | 2.35±0.86 | 2.16±0.69 | 65.96±11.78 |
| Post treatment | 1.46±0.58* | 1.0±0.73* | 1.48±0.65* | 76.4±11.78* | ||
| Placebo group (N=20) | Baseline | |||||
| Post treatment | No significant changes | No significant changes | No significant changes | No significant changes | ||
| S. Nirala 2016 [73] | Test group (N=41) | Baseline | 2.21±0.85 | 1.34±1.35 | 1.85±0.96 | 66.34±12.34 |
| Post treatment | 1.14±0.57 | 0.21±0.82* | 1.04±0.49** | 79.92±25.14** | ||
| Control group (N=11) | Baseline | 1.81±0.75 | 1.36±1.62 | 1.36±0.67 | 84±7.61 | |
| Post treatment | 2.18±0.75 | 2±1.18 | 2.09±0.94 | 72.72±12.33 | ||
| Y. Kikuchi 2010 [31] | Test group (N=8) | Baseline | 3.0 | 4.0 | - | - |
| Post treatment | 2.25* | 1.0* | - | - | ||
| Placebo group (N=8) | Baseline | 2.75 | 4.0 | - | - | |
| Post treatment | 2.75 | 3.0* | - | - | ||
| W.H. Kazmi 2012 [71] | Test group (N=43) | Baseline | 2.63±0.7 | - | 2.48±0.6 | - |
| Post treatment | 1.95±0.8** | - | 1.95±0.5** | - | ||
| Control group (N=43) | Baseline | 2.63±0.7 | - | 2.48±0.6 | - | |
| Post treatment | 2.63±0.7 | - | 2.46±0.6 | - | ||
| G. Alunni 2014 [72] | Test group (N=43) | Baseline | 2.67±0.75 | 26(60.5%) | 2.51±0.74 | - |
| Post treatment | 1.33±0.57** | 9 (20%)* | 1.23±0.42** | - | ||
| Control group (N=29) | Baseline | 2.52±0.78 | 18 (41%)* | 2.32±0.79 | - | |
| Post treatment | 1.92±0.69 | 13 (44.8%)* | 1.73±0.59 | - |
CCS Canadian Cardiovascular Society Angina Class, nitroglycerine consumption is expressed as number of tablets per day, NYHA New York Heart Association class, * = p<0.05 compared to baseline, ** = p<0.001 compared to baseline